Acceleration of left-ventricular diastolic dysfunction and pulmonary hypertension after TNF-alpha blocker.
Korkmaz
Cengiz
C
Kaşifoglu
Timuçin
T
Yaşar
Bilnur
B
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003971:Diastole / Q000187:drug effects / Q000502:physiology; D017809:Fatal Outcome; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced*; D000069285:Infliximab; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab